WO2022245574A1 - Feedback system and method for a drug product - Google Patents
Feedback system and method for a drug product Download PDFInfo
- Publication number
- WO2022245574A1 WO2022245574A1 PCT/US2022/028430 US2022028430W WO2022245574A1 WO 2022245574 A1 WO2022245574 A1 WO 2022245574A1 US 2022028430 W US2022028430 W US 2022028430W WO 2022245574 A1 WO2022245574 A1 WO 2022245574A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dose
- reminder
- user
- drug product
- drug delivery
- Prior art date
Links
- 229940126534 drug product Drugs 0.000 title claims abstract description 197
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 197
- 238000000034 method Methods 0.000 title claims description 67
- 238000013459 approach Methods 0.000 claims abstract description 13
- 238000012377 drug delivery Methods 0.000 claims description 173
- 230000008713 feedback mechanism Effects 0.000 claims description 36
- 230000000007 visual effect Effects 0.000 claims description 34
- 238000002347 injection Methods 0.000 claims description 32
- 239000007924 injection Substances 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 22
- 230000003213 activating effect Effects 0.000 claims description 21
- 230000001755 vocal effect Effects 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- 230000009471 action Effects 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 8
- 238000004891 communication Methods 0.000 claims description 8
- 230000003442 weekly effect Effects 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000012549 training Methods 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 4
- 230000008447 perception Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 2
- 238000012790 confirmation Methods 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 229950000128 lumiliximab Drugs 0.000 description 49
- 239000000047 product Substances 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 33
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 108010074604 Epoetin Alfa Proteins 0.000 description 13
- 102100034980 ICOS ligand Human genes 0.000 description 8
- 229960000106 biosimilars Drugs 0.000 description 8
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 7
- 108010019673 Darbepoetin alfa Proteins 0.000 description 7
- 229960003388 epoetin alfa Drugs 0.000 description 7
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 6
- 102000002265 Human Growth Hormone Human genes 0.000 description 6
- 108010000521 Human Growth Hormone Proteins 0.000 description 6
- 239000000854 Human Growth Hormone Substances 0.000 description 6
- 229940127276 delta-like ligand 3 Drugs 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 5
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 5
- 102000003812 Interleukin-15 Human genes 0.000 description 5
- 108090000172 Interleukin-15 Proteins 0.000 description 5
- 230000010437 erythropoiesis Effects 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 4
- 102100036509 Erythropoietin receptor Human genes 0.000 description 4
- 108010008165 Etanercept Proteins 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000003173 antianemic agent Substances 0.000 description 4
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 108010002601 epoetin beta Proteins 0.000 description 4
- 229960004579 epoetin beta Drugs 0.000 description 4
- 108010067416 epoetin delta Proteins 0.000 description 4
- 229950002109 epoetin delta Drugs 0.000 description 4
- 108010081679 epoetin theta Proteins 0.000 description 4
- 229950008826 epoetin theta Drugs 0.000 description 4
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 description 4
- 229960000598 infliximab Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 4
- ZJNLYGOUHDJHMG-UHFFFAOYSA-N 1-n,4-n-bis(5-methylhexan-2-yl)benzene-1,4-diamine Chemical compound CC(C)CCC(C)NC1=CC=C(NC(C)CCC(C)C)C=C1 ZJNLYGOUHDJHMG-UHFFFAOYSA-N 0.000 description 3
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 108091006020 Fc-tagged proteins Proteins 0.000 description 3
- 101710093458 ICOS ligand Proteins 0.000 description 3
- 102100030704 Interleukin-21 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 102000014128 RANK Ligand Human genes 0.000 description 3
- 108010025832 RANK Ligand Proteins 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 3
- 229960005029 darbepoetin alfa Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108010030868 epoetin zeta Proteins 0.000 description 3
- 229950005185 epoetin zeta Drugs 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- ANIAZGVDEUQPRI-ZJQCGQFWSA-N etelcalcetide Chemical compound NC(N)=NCCC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O ANIAZGVDEUQPRI-ZJQCGQFWSA-N 0.000 description 3
- 229950006502 etelcalcetide Drugs 0.000 description 3
- 108091022127 etelcalcetide hydrochloride Proteins 0.000 description 3
- 102000044389 human CD22 Human genes 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 108010074108 interleukin-21 Proteins 0.000 description 3
- 229960001972 panitumumab Drugs 0.000 description 3
- 108010044644 pegfilgrastim Proteins 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 102100024654 Calcitonin gene-related peptide type 1 receptor Human genes 0.000 description 2
- 101710118454 Calcitonin gene-related peptide type 1 receptor Proteins 0.000 description 2
- 102000013602 Cardiac Myosins Human genes 0.000 description 2
- 108010051609 Cardiac Myosins Proteins 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 108010033266 Lipoprotein(a) Proteins 0.000 description 2
- 229940098712 Myosin activator Drugs 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 2
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 2
- 108010039185 Tenecteplase Proteins 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960001164 apremilast Drugs 0.000 description 2
- 229940115115 aranesp Drugs 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229960003735 brodalumab Drugs 0.000 description 2
- 229950007296 cantuzumab mertansine Drugs 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- 229960002438 carfilzomib Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 229950007276 conatumumab Drugs 0.000 description 2
- 239000003962 counterfeit drug Substances 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- 229960002224 eculizumab Drugs 0.000 description 2
- 229940073621 enbrel Drugs 0.000 description 2
- 229940089118 epogen Drugs 0.000 description 2
- 229950009760 epratuzumab Drugs 0.000 description 2
- 229950001616 erenumab Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 229950004896 ganitumab Drugs 0.000 description 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 229940048921 humira Drugs 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010010648 interferon alfacon-1 Proteins 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
- 229960000994 lumiracoxib Drugs 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229950001869 mapatumumab Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940029238 mircera Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 108010046821 oprelvekin Proteins 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940116176 remicade Drugs 0.000 description 2
- 229950003238 rilotumumab Drugs 0.000 description 2
- 108010017584 romiplostim Proteins 0.000 description 2
- 229950010968 romosozumab Drugs 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 229950001212 volociximab Drugs 0.000 description 2
- 229950008250 zalutumumab Drugs 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- UHTZABZWCSJMDY-UHFFFAOYSA-N 2-(chloromethyl)oxirane;n,n,n',n'-tetrakis(3-aminopropyl)butane-1,4-diamine Chemical compound ClCC1CO1.NCCCN(CCCN)CCCCN(CCCN)CCCN UHTZABZWCSJMDY-UHFFFAOYSA-N 0.000 description 1
- PFWVGKROPKKEDW-UHFFFAOYSA-N 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid Chemical compound C=1C=C(C2CC2)C=C(Cl)C=1S(=O)(=O)NC1=CC(C(=O)NC(C)(C)C)=CC=C1OC1=CC(F)=C(CC(O)=O)C=C1Cl PFWVGKROPKKEDW-UHFFFAOYSA-N 0.000 description 1
- HPNRHPKXQZSDFX-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[6-amino-2-[[52-[[2-[[2-[[2-[[5-amino-2-[[2-[[2-[[6-amino-2-[[1-(2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-butan-2-yl-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound N1C(=O)C(NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C2N(CCC2)C(=O)C(N)CO)C(C)C)CSSCC(C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2N=CNC=2)C(O)=O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C1CC1=CC=CC=C1 HPNRHPKXQZSDFX-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 1
- AVVVYDOYYJBULZ-UHFFFAOYSA-N 2-methyl-4-oxo-6-(pyridin-3-ylmethylamino)-1h-pyrimidine-5-carbonitrile;hydrochloride Chemical compound Cl.N1C(C)=NC(=O)C(C#N)=C1NCC1=CC=CN=C1 AVVVYDOYYJBULZ-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 102000018746 Apelin Human genes 0.000 description 1
- 108010052412 Apelin Proteins 0.000 description 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229960005509 CAT-3888 Drugs 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- JQNINBDKGLWYMU-GEAQBIRJSA-N CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 Chemical compound CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 JQNINBDKGLWYMU-GEAQBIRJSA-N 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 1
- 101100179591 Caenorhabditis elegans ins-22 gene Proteins 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 101150043052 Hamp gene Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010017411 Interleukin-21 Receptors Proteins 0.000 description 1
- 102100030699 Interleukin-21 receptor Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 1
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
- 101710148535 Thrombopoietin receptor Proteins 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229940062744 acapatamab Drugs 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002691 anti-thymic effect Effects 0.000 description 1
- 229940127131 antibody-peptide-conjugate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 229950009925 atacicept Drugs 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229950007940 bixalomer Drugs 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 229940101815 blincyto Drugs 0.000 description 1
- 229950005042 blosozumab Drugs 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 108700001003 carbamylated erythropoietin Proteins 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 229940088128 efavaleukin alfa Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 108010090921 epoetin omega Proteins 0.000 description 1
- 229950008767 epoetin omega Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 229940063135 genotropin Drugs 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010013846 hematide Proteins 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 102000049885 human IL11 Human genes 0.000 description 1
- 102000053529 human TNFSF11 Human genes 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 229940065770 humatrope Drugs 0.000 description 1
- 229940091204 imlygic Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 229940000764 kyprolis Drugs 0.000 description 1
- 229950010470 lerdelimumab Drugs 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229940054205 natrecor Drugs 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- RFUBTTPMWSKEIW-UHFFFAOYSA-N omecamtiv mecarbil Chemical compound C1CN(C(=O)OC)CCN1CC1=CC=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1F RFUBTTPMWSKEIW-UHFFFAOYSA-N 0.000 description 1
- 229950001617 omecamtiv mecarbil Drugs 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 229940011530 otezla Drugs 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 108010048732 pegylated erythropoietin Proteins 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 229940028952 praluent Drugs 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 229940029359 procrit Drugs 0.000 description 1
- 229940092597 prolia Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 229940017164 repatha Drugs 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 229940121606 rozibafusp alfa Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 229940055944 soliris Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940073531 sotorasib Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940071598 stelara Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229950008461 talimogene laherparepvec Drugs 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 229950008998 tezepelumab Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 108010075758 trebananib Proteins 0.000 description 1
- 229950001210 trebananib Drugs 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229950009578 vidupiprant Drugs 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 229940014556 xgeva Drugs 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 229940051223 zetia Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Definitions
- the present disclosure generally relates to reminder systems for drug products and, more particularly, to a customized system and method of managing reminders for a user to dose a drug product and providing feedback to the user as to the status of the dose.
- Non-daily medication doses such as injections
- Patients have a range of lifestyles from more organized to unstructured routines. As such, it is common for many patients to inadvertently skip a dose, stretch a dose, and/or discontinue a dose of a needed medication. Often times, such patients skip or miss a dose of a needed medication at the last minute without an intention to skip.
- this problem is identified within the first few months of a given therapy, as patients are largely stretching their medication in this scenario.
- many drug delivery devices such as autoinjectors, must also provide feedback to the user as to the status of the dose once the patient begins taking the dose of needed medication, for example.
- the drug delivery device provides signals to the user during the dose for the user to gauge progress.
- These functions are most cost effectively done with visual, audible, and sometimes tactile mechanisms.
- low energy Bluetooth devices were relied on to allow a smart user device to connect with the drug delivery device, such as the autoinjector.
- these connections suffer from added complexity, costs, and often the need for chemical batteries, which may be hazardous to dispose of and represent a potential weak point from a reliability perspective.
- a reminder device for reminding a user when to dose a drug product.
- the reminder device comprises a body having a touch screen and a button, a motion sensor carried by the body, an audible indicator carried by the body for generating an audible alarm, and a memory carried by the body and storing a dosing schedule and a reminder schedule.
- Each of the dosing schedule and the reminder schedule are based on user input via the touch screen, and the dosing schedule includes at least one date for a dose of the drug product, and the reminder schedule includes at least one time for activating the audible alarm.
- the reminder device further comprises a processor carried by the body and configured to access the dosing schedule and the reminder schedule and execute logic stored on the memory to cause the touch screen to display a countdown timer for reminder the user of the at least one date for the dose, the countdown timer updating as the at least one date for the dose approaches and comprising a visible indicator that is activated: (1) upon actuation of the button on the body; or (2) automatically at a set time before the at least one date of the dose and upon sensing motion via the motion sensor.
- the processor also executes logic stored on the memory to cause the audible alarm to activate at the at least one time for the dose.
- a reminder system for reminding a user when to dose a drug product.
- the reminder system comprises a wireless network, at least one remote database operatively coupled to the wireless network, and a reminder device operatively coupled to the wireless network.
- the reminder device comprises a body having a touch screen and a button, a motion sensor carried by the body, an audible indicator carried by the body for generating an audible alarm, and a memory carried by the body and storing a dosing schedule and a reminder schedule.
- Each of the dosing schedule and the reminder schedule are based on user input via the touch screen, and the dosing schedule includes at least one date for a dose of the drug product, and the reminder schedule includes at least one time for activating the audible alarm.
- the reminder device further comprises a processor carried by the body and configured to access the dosing schedule and the reminder schedule and execute logic stored on the memory to cause: (A) the touch screen to display a countdown timer for reminder the user of the at least one date for the dose, the countdown timer updating as the at least one date for the dose approaches and comprising a visible indicator that is activated: (1) upon actuation of the button on the body; or (2) automatically at a set time before the at least one date of the dose and upon sensing motion via the motion sensor; and (B) the audible alarm to activate at the at least one time for the dose.
- a method of managing reminders for a user to dose a drug product comprises, upon actuating a reminder device, displaying a countdown timer on a touch screen of the reminder device, the countdown timer for reminding a user of at least one date for a dose of a drug product set by a user.
- the method also comprises updating the countdown timer as the at least one date for the dose approaches.
- the method also includes activating a visible indicator of the countdown timer: (1) upon actuating a button of the reminder device; and (2) automatically at a set time before the at least one date for the dose and upon sensing motion via motion sensor.
- the method still also includes activating an audible alarm of an audible indicator of the reminder device at a time set by the user.
- the reminder device, the reminder system and/or method of managing reminders for a user to dose a drug product may further include any one or more of the following preferred forms.
- the logic may be further executable by the processor to automatically change the touch screen to a color indicating the dose is past due.
- the body may include one or more of: (1) a magnet adapted to attach to a surface of a refrigerated compartment storing the drug product; or (2) a surface adapted to be coupled to a stand disposed near the drug product.
- each of the dosing schedule and the reminder schedule may include a frequency, such as weekly, every two weeks, monthly, twice weekly, once every number of months, or once every number of days, the number able to be set to a desired value
- the reminder device may further comprise a user-configured wireless communication module for wireless transmission of a text message reminder to a user device, and the text message may be transmitted one or more of: (1) at the date the dose is due, or (2) when the dose is past due.
- the reminder device may further comprise a log of information about depersonalized user actions collected by the processor and stored in the memory, and a user-configured wireless communication module for wireless transfer of the log of information to a remote database.
- the reminder device may further comprise a temperature timer configured to alert the user when the drug product has been out of a refrigerated compartment for a sufficient time, allowing the drug product to reach a desired temperature, such as room temperature.
- the logic may be further executable by the processor to provide an option to reorder on the touch screen, and the option to reorder may be activated based on user input via the touch screen.
- the at least one remote database of the reminder system may comprise a database for receiving a log of information including depersonalized actions collected by the processor of the reminder device or a database for receiving personalized used actions collected by the processor.
- Each of the databases may prepare reports for the logs of information.
- the reminder system may further comprise a user device.
- the user device may be coupled to the wireless network and may be for receiving a text message reminder from the reminder device.
- the text message reminder may be sent one or more of at the at least one date for the dose or when the dose is past due.
- the method may further comprise storing, via a memory of the reminder device, one or more of a dosing schedule and a reminder schedule based on input from the user.
- the dosing schedule may include the at least one date for a dose of the drug product
- the reminder schedule may include the time for activating the audible alarm.
- the method may further comprise automatically changing the touch screen of the reminder device to a color indicating the dose is past due, providing another reminder to the user.
- the method may further comprise transmitting, via a processor of the reminder device, a text message reminder to a user device via a wireless network at the at least one date for the dose or when the dose is past due, and the text message reminder may include the at least one date for the dose.
- the method may comprise actuating the touch screen on the reminder device in response to the audible alarm to initiate a snooze function for the audible alarm and for a period of time, and automatically reactivating the audible alarm after the period of time expires.
- the method may further comprise activating a temperature timer before the at least one date for the dose, the temperature timer configured to alert the user when the drug product has been out of a refrigerated compartment for a sufficient time, allowing the drug product to reach a desired temperature, such as room temperature.
- a feedback system for use with a dose of a drug product comprises a wireless network, a drug delivery device including a body and an audible indicator carried by the body and for generating one or more audible signals, and an intermediary device operatively coupled to the drug delivery device and the wireless network.
- the intermediary device includes a body having a microphone configured to amplify the one or more audible signals generated by the drug delivery device; at least one feedback mechanism carried by the body, a memory and a processor carried by the body.
- the processor is configured to execute logic stored on the memory to cause the at least one feedback mechanism to provide feedback to the user about a dose of the drug product based on the one or more audible signals generated by the drug delivery device, and the feedback includes one or more of an audio indication or a visual indication.
- a method of providing feedback to a user about a dose of a drug product comprises receiving, via an intermediary device, one or more audible signals generated by a drug delivery device, and the intermediary device is operatively coupled to a wireless network and the drug delivery device.
- the method further comprises providing feedback to a user about a dose of a drug product of the drug delivery device via at least one feedback mechanism of the intermediary device based on the one or more audible signals.
- the feedback includes one or more of an audio indication or a visual indication.
- Fig. 1 is a perspective view of a reminder system of the present disclosure
- FIG. 2 is block diagram of portions of the reminder system of Fig. 1 ;
- FIG. 3 is a perspective view of a reminder device of the reminder system according to one embodiment
- Fig. 4A is a perspective view of a touch screen of the reminder device of the present disclosure.
- Figure 4B is a view of optional displays on a touch screen of the reminder device of the present disclosure, the optional displays indicating a stage of the reminder device of the present disclosure;
- Fig. 5 is a flow chart illustrating a method of setting up a wireless communication module with the reminder device of the present disclosure
- Fig. 6 is a flow chart illustrating a method of customizing, including setting an actual time and date, the reminder device of the present disclosure
- Fig. 7 is a flow chart illustrating a method of setting a dosing schedule for a dose of a drug product and a reminder schedule with the reminder device of the present disclosure
- Fig. 8 is a flow chart illustrating a method of selecting features of a reminder of the reminder system of the present disclosure
- Fig. 9 is a flow chart illustrating a method of selecting a text reminder with the reminder device of the present disclosure
- Fig. 10 is flow chart illustrating a countdown displayed on a touch screen of the reminder device during different periods of time before the selected date and time of a dose of the drug product;
- Fig. 11 is a block diagram of a feedback system of the present disclosure.
- Fig. 12 is another block diagram of the feedback system of Fig. 11 , with the reminder device;
- Fig. 13 is a block diagram of portions of the feedback system of Fig. 12;
- Fig. 14 is an exemplary visual indication of an intermediary device of the feedback system of Figs. 11 and 12;
- Fig. 15 is another exemplary visual indication of the intermediary device of the feedback system of Figs. 11 and 12;
- Fig. 16 is another exemplary visual indication of the intermediary device of the feedback system of Figs. 11 and 12;
- Fig. 17 is another exemplary visual indication of the intermediary device of the feedback system of Figs. 11 and 12;
- Fig. 18 is a listing of other exemplary visual indications of the feedback system of Figs. 11 and 12 of the present disclosure.
- a system and method that utilize a reminder device for reminding a user when to dose a drug product.
- the reminder device is designed to aid patients in managing a non-daily, self-injectable drug product, such as a biologic, and provides multiple reminders, including visual and audible reminders, and an optional text message reminder.
- the reminder device may be attached to a refrigerated compartment storing the drug product or disposed near the drug product to facilitate ease of injection after the reminders.
- the reminder device includes a body having a touch screen, a button, a motion sensor carried by the body, an audible alarm, a power source, such as a battery, and a memory for storing the dosing and reminder schedules, and a processor to execute logic stored on the memory to cause the touch screen to display a countdown timer for reminding the user of at least one date for the dose of the drug product.
- the countdown timer is updated as the at least one date for the dose approaches and comprises a visible indicator, which is activated upon actuation of a button or automatically at a set time before the at least one time for the dose and upon sensing motion via the motion sensor.
- the processor also executes logic stored on the memory to cause the audible alarm to activate at the at least one time for the dose. While the user is required to input the dosing and reminder schedules, any specific drug product is never entered into and/or associated with the reminder device or system of the present disclosure. Moreover, the dosing and reminder schedules set by the user are for a single drug product, and the reminder device and system do not accommodate dosing and reminder schedules for multiple drug products.
- a system and method are disclosed that utilize an existing, wireless intermediary device, such as the reminder device or another smart device, to provide feedback to the user about the dose of the drug product based on audible signals generated by a drug delivery device. More specifically, the system and method use existing audible feedback mechanisms on drug delivery devices as a connection to the intermediary device, e.g., the reminder device.
- the intermediary device is able to discern at a minimum audible signals from the drug delivery device associated with a start and an end of the dose of the drug product, such as an injection, and provide feedback to the user based on the audible signals from the drug delivery device.
- the intermediary device augments feedback in form of the audible signals from the drug delivery device with louder and/or more descriptive feedback to the user.
- the reminder system 10 includes the reminder device 12 having a body 14 with a touch screen 16 and a button 18.
- the touch screen 16 is a color touch screen.
- the reminder device 12 also includes a motion sensor 20 carried by the body 14. While the motion sensor 20 is disposed on a lower area of the body 14, it will be appreciated that the motion sensor 20 may be disposed on any part of the reminder device 12 and still fall within the scope of the present disclosure.
- the reminder device 12 further includes an audible indicator 22 carried by the body 14 and for generating an audible alarm, a processor 24, and a memory 26, and each of the processor 24 and memory are also carried by the body 14.
- the memory 26 stores a dosing schedule and a reminder schedule, and each of the dosing schedule and the reminder schedule are based on user input provided via the touch screen 16 of the reminder device 12, as also described more below.
- the dosing schedule includes at least one date for the dose inputted by the user
- the reminder schedule includes at least one time for activating the audible alarm of the audible indicator 22.
- the processor 24 is configured to access the dosing schedule and the reminder schedule and execute logic stored on the memory 26 to cause: (A) the touch screen 16 to display a countdown timer 27 for reminding the user of the at least one date for the dose.
- the countdown timer 27 updates as the at least one date for the dose approaches and comprises a visible indicator 28.
- the visible indicator 28 may include text or a color on a display of the touch screen 16, as explained more below.
- the visible indicator 28 may be activated upon actuation of the button 18 on the body 14 of the reminder device 12. Further, the visible indicator 28 may also be automatically activated at a set time before the at least one date of the dose and upon sensing motion via the motion sensor 20.
- the processor 24 may also execute logic stored on the memory 26 to cause the audible alarm of the audible indicator 22 to activate at the least one time for the dose, as also explained more below.
- the reminder device 12 includes a power source 30, which may include a battery or a wired connection, a power/charge port 32, a temperature timer 33, and a magnet or magnetic portion 34.
- the power/charging port 32 is used for powering the power source 30, such as a battery, of the reminder device 12, and no data can be accessed from the reminder device 12 via this port 32.
- the magnet or magnetic portion 34 of the reminder device 12 may be attached to a surface of a refrigerated compartment 35 storing the drug product 37, such as the drug product for injection.
- the temperature timer 33 may be activated for a period of time, such as 30 minutes, when the audible alarm 22 is activated, enabling the drug product 37 to be prepared for the dose, as also explained more below.
- the temperature timer 33 is configured to alert the user when the drug product has been out of the refrigerated compartment 35 for a sufficient time, allowing the drug product to reach a desired temperature, such as room temperature.
- the reminder system 10 also includes a wireless network 36, and the reminder device 12 may be operatively coupled to the wireless network 36 via a Wi-Fi router 38 of the user.
- the reminder system 10 also includes at least one remote database operatively coupled to the wireless network 36.
- the reminder device 12 supports an optional Wi-Fi connection that allows it to connect to an SMS server and the at least one remote database.
- the reminder system 10 includes a first database 40, such as a cloud mine database, for receiving a log of information about depersonalized user actions collected by the processor 24 and stored in the memory 26 of the reminder device 12.
- the reminder system 10 may also include a second database 42 for receiving a log of information about personalized user actions again collected by the processor 24 and stored in the memory 26 of the reminder device 12.
- the logs of information include usage logs that allow administrators to understand patients’ usage of the reminder device 12, including how compliant they have been in taking their drug products.
- the data included in the logs of information may include, but is not limited to, several events, such as a dose ready alarm, a missed alarm, a timer is ready, a timer missed alarm, a text sent regarding drug product dose, a low battery indicator, and if Wi-Fi setup failed.
- the data in the logs of information may also include data about user actions, such as when did the first start up/initialization occur, when a timer was used, if an alarm was dismissed, if a user actuated a “take now” button on the touch screen 16, if the reminder device 12 was plugged into a charger, and if a Wi-Fi connection was established.
- user actions such as when did the first start up/initialization occur, when a timer was used, if an alarm was dismissed, if a user actuated a “take now” button on the touch screen 16, if the reminder device 12 was plugged into a charger, and if a Wi-Fi connection was established.
- the first database 40 includes a processor 45, a memory 46, and a network interface 47
- the second database 42 also includes a processor 48, a memory 49, and a network interface 50.
- the processors 45, 48 of each of the first and second databases 40, 42 receive the logs of information from the reminder device 12 and may generate reports based on the collected information.
- the user device 44 of the reminder system 10 also includes at least a processor 51, a memory 52, and a network interface 53 operatively coupled to the wireless network 36 and through which the text reminder from the reminder device 12 is transmitted.
- the reminder device 12 of the reminder system 10 is depicted.
- the reminder device 12 is not coupled to the refrigerated compartment 35 via the magnet 34 of the reminder device 12, as in Fig. 1.
- the reminder device 12 is disposed in a stand 54.
- the stand 54 includes a base 56, a pair of support members 58 upwardly extending from and connected to the base 56, and a body 60 having a first end 62 to which the pair of support members 58 are connected and second end 64 adapted to contact a surface 66 disposed near the storage of the drug product 37. So configured, the body 60 extends downwardly from the pair of support members 58.
- the second end 62 of the body 60 of the base 56 also includes a pair of projections 68.
- the reminder device 12 is disposed on the body 60, such that one end of the reminder device 12 is maintained in place on the body 60 via the pair of projections 68, for example.
- the stand 54 may take the form of various other shapes, sizes, and examples that function in a manner similar to or the same as the stand 54 and still fall within the scope of the present disclosure. The stand 54 helps dispose the touch screen 16 and the reminder device 12 at an angle, instead of a horizontal position on a relatively flat surface, so that the touch screen 16 is readily visible to the user.
- exemplary displays on the touch screen 16 of the reminder device 12 of the present disclosure are depicted.
- a perspective view of the touch screen 16 of the reminder device 12 is depicted after a user has inputted a date and time for the dose of the drug product and a reminder for activation of the audible alarm of the audible indicator 22.
- the user has inputted that the dose of the drug product should be taken every 14 days and the audible alarm of the audible indicator 22 is activated every other Thursday.
- the user also selected a custom screen saver (e.g., of her pet) as displayed in the background of the touch screen 16 of the reminder device 12.
- the displayed screen saver is an example only, and various other alternative screen savers may alternatively be used and customized on the touch screen 16 of the reminder device 12.
- Figure 4B depicts displays on the touch screen 16 of the reminder device 12, each of which is displayed at a different time during use of the reminder device 12. For example, at a time T 1 , the touch screen 16 displays text asking a user if he or she wishes to “get started”. If yes, the user contacts the touch screen 16 at the location of the arrow displayed thereon and is prompted to input various settings, a dosing schedule, and a reminder schedule, as explained more below.
- the touch screen 16 displays text indicating the reminder device 12 is ready for operation at a time T2.
- the reminder device 12 then provides reminders based on both the user inputted dosing schedule and the reminder schedule until the dose of the drug product 37 has been taken, as inputted by the user.
- the touch screen 16 of the reminder device 12 displays text asking if a user desires to reorder the drug product 37.
- the reordering may be conducted via the reminder device 12 and/or via the user device 44 via the wireless network 36, for example.
- the drug product may be reordered using any other known means for reordering the drug product.
- Figs. 5-9 various flow charts depicting processes for setting up and customizing the reminder device 12 of the present disclosure are depicted.
- Fig. 5A a process of setting up and establishing a wireless communication module with the reminder device 12 of the present disclosure is depicted.
- the touch screen 16 upon powering on the reminder device 12, the touch screen 16 first indicates that a Wi-Fi connection allows for complete functionality in step 102. If the user touches the “next” touch button 70 displayed on the touch screen 16, the touch screen 16 then indicates in step 104 that Wi-Fi simplifies set up and allows for text messaging alerts. The user may again via the touch screen 16 contact the “next” touch button to advance the display on the touch screen 16 in step 106.
- step 106 the touch screen 16 indicates a Wi-Fi enabled smart phone or device is required.
- the touch screen 16 Upon contacting the “next” touch button 70 again on this display, the touch screen 16 then asks the user if a Wi-Fi connection is desired in step 108. If the user selects the SKIP button as in step 110, the touch screen 16 then displays a prompt for the user to enter the current time and date in step 112, which is explained more below in Fig. 6. However, if the user selected the YES button as in step 108, the touch screen 16 displays the text in step 114 to connect the user’s device to a specific network.
- the touch screen 16 Upon doing so, the touch screen 16 then displays text indicating the user should utilize the browser of the user device 44 to go to a website of the reminder device 12, such as MyRemo.net.
- the touch screen 16 prompts the user to enter his or her Wi-Fi network name and password into the website of the reminder device 12, thereby establishing a user-configured wireless communication module with the reminder device 12, for example.
- the touch screen 16 indicates to the user that the reminder device 12 is attempting to connect to the wireless network 36, for example, and then indicates on the touch screen 16 when the reminder device 12 is connected, as in step 122.
- the touch screen 16 will display an error message, as in step 126, which then routes the user back to the display on the touch screen 16 of the reminder device 12 in step 108.
- the user may further customize the touch screen 16 of the reminder device 12, such as by selecting a background or screen saver, as indicated in step 124. It will be appreciated that the user may at any time contact the “back” touch button 72 on any of the displays of the touch screen 16 in the steps of Fig. 5, which will take the user to the previously viewed display on the touch screen 16 of the reminder device 12.
- a flow chart illustrating an exemplary process for setting up the current time and date on the reminder device 12 is depicted.
- the touch screen 16 first displays text prompting the user to enter the current time and date.
- the touch screen 16 Upon selecting the “next” touch button 70 on the touch screen 16 of the reminder device 12, the touch screen 16 then provides a prompt for the user to enter the current time in step 204.
- the user utilizes the up and down arrows 76 to set the current time.
- the user again selects the “next” touch button 70 to advance to the display on the touch screen 16 in step 206.
- the user is then prompted to enter the current date, again using the up and down arrows 76 to do so.
- the touch screen 16 provides another opportunity for the user to customize the reminder device 12, such as by selecting a background for the touch screen 16 of the reminder device 12 in step 208.
- the touch screen 16 displays prompts for setting a dosing schedule for a dose of the drug product and a reminder schedule for the reminder device 12. Specifically, the touch screen 16 first prompts the user to select a date for the dose in step 302. Then the touch screen 16 prompts the user to select a day for the dosing schedule using the up and down arrows 76 provided on the display of the touch screen 16, as in steps 304, 306, and 308. In particular, the touch screen 16 includes a month and a day within the month, e.g., the date, both of which are individually selected via the up and down arrows 76.
- step 306 the user moved the up and down arrows 76 in step 304 to change the day in the month of February from 01 to 02 in step 306.
- step 308 the user moved the up and down arrows 76 to change the month from February to March.
- step 310 the touch screen 16 next provides a prompt regarding how often the user takes his or her drug product.
- the touch screen 16 Upon actuation of the “next” button by the user in step 310, the touch screen 16 provides three options regarding the frequency of the dose of the drug product. Specifically, in step 312, the touch screen 16 provides a button indicating the drug product is taken weekly, another button indicating the drug product is taken every two weeks, i.e., bi-weekly, and a third button indicating the drug product is taken monthly.
- the user next selects one of the buttons corresponding to the accurate frequency of the dose of the drug to finalize the dosing schedule for the reminder device 12.
- the user selected the button corresponding to the weekly frequency, but it will be understood that a user may alternatively select either of the other buttons to set the dosing schedule.
- a user may input a frequency of dose the same as or different from the three example frequencies listed in step 312 via a numerical input, such as by way of his or her user device 44 operably coupled to the reminder device 12 and still fall within the scope of the present disclosure.
- the frequency may be weekly, bi-weekly, monthly, twice weekly, once every number of months, or once every number of days, and the user is able to set the number to a desired value, such as 2, 3 or 4, for example. It will be understood that any of these example frequencies may be used and still fall within the scope of the present disclosure.
- the touch screen 16 displays prompts for setting a reminder schedule for the reminder device 12, as also depicted in Fig. 7. Specifically, in step 314, the touch screen 16 first displays a prompt for the user to set the time for a reminder for an alarm, such as the audible alarm of the audible indictor 22 of the reminder device 12. Upon actuating the “next” button on the touch screen 16 to set the time for the reminder, the touch screen 16 next prompts the user to select a time using the up and down arrows 76, as depicted in step 316. In steps 318, 320, and 322, the touch screen 16 displays a prompt including a different frequency for the reminder for the alarm.
- step 318 the touch screen 16 displays a prompt indicating the reminder will occur every week starting at a specific date and time.
- the touch screen 16 displays a prompt indicating the reminder will occur every two weeks, i.e., bi-weekly, starting at a specific date and time.
- the touch screen 16 displays a prompt indicating the reminder will occur each month starting at a specific date and time.
- the current time and date are displayed in a top area of the touch screen 16.
- the touch screen 16 Upon selection of one of the three times provided in steps 318, 320 or 322 for the reminder to occur, the touch screen 16 next displays a prompt for selecting a sound for the audible alarm of the audible indicator 22 in step 324, as explained in Fig. 8. In each of the steps of selecting the reminder schedule in Fig. 7, the touch screen 16 displays the “back” and the “next” buttons 70, 72, which the user may contact to move between displays of the touch screen 16, as needed when selecting and setting the reminder schedule for the reminder device 12.
- step 402 the touch screen 16 initially displays a prompt indicating the user may select a tune or song and a volume for the audible alarm.
- step 404 the touch screen 16 displays a prompt including three “tunes” for selection, one of which may be selected by the user. While three “tunes” for selection are displayed in step 404, it will be appreciated that a greater amount of songs may additionally be accessed and selected and still fall within the scope of the present disclosure.
- the touch screen 16 next displays a prompt listing three volume levels for the song when the audible alarm of the audible indicator 22 is activated. Specifically, the three volume levels listed include loud, medium, and quiet, and the user selects one of the three volumes displayed. Lastly, in step 408, the touch screen 16 next displays a prompt indicating that text messages may optionally be sent to the user’s device 44, e.g., the smart phone, such as when the audible alarm of the audible indicator 22 is missed.
- the touch screen 16 of the reminder device 12 includes additional prompts for setting the text message reminder. Specifically, upon selecting the “next” button 70 in step 502 of Fig. 9, the touch screen 16 displays a prompt to enable the text message reminder in step 504. Upon actuation of the “yes” button in step 504 to enable the text message reminder, the touch screen 16 next displays a prompt requiring the user to enter a phone number for the text message reminder to be sent in step 506. In step 508, the touch screen 16 displays a number keyboard for the user to enter the phone number.
- the touch screen 16 of the reminder device 12 indicates the reminder device 12 is ready for use and may be secured to the refrigerated compartment 35 (Fig. 1) or the stand 54 (Fig. 3), for example, in step 510.
- the touch screen 16 of the reminder device 12 displays the selected background or screen saver, the actual date and time, and a countdown timer indicating a number of days until the dose of the drug product is due (based on the dosing schedule inputted).
- the touch screen 16 displays the countdown timer 27 for reminding the user of the set date for the dose of the drug product, as depicted in Fig. 10.
- a countdown timer 27 on the touch screen 16 is a visual reminder to the user.
- the countdown timer 27 is updated as at least one date and time for dose approach.
- the countdown timer 27 includes the visible indicator 28 that is activated upon actuation of the button 18 (Fig. 1) of the reminder device 10.
- the visible indicator 28 may also be automatically activated at a set time before the at least one date and time of the dose and upon sensing motion via the motion sensor 20.
- the motion sensor 20 is activated once the countdown timer 27 reaches a time shortly before the at least one date of the dose, such as the day before or another time shortly before the dose due date.
- the countdown timer 27 begins 14 days before the set date of the dose of the drug product in step 602. While not depicted in Fig. 10, the countdown timer 27 of the reminder device 12 typically counts in single day units.
- the touch screen 16 of the reminder device 12 displays the countdown timer 27, indicating there are 10 days until the date of the dose and an associated reminder, such as the audible alarm of the audible indicator 22, for example.
- step 606 the touch screen 16 of the reminder device 12 displays the updated countdown timer 27, indicating there are 2 days left.
- the countdown timer 27 switches to “TOMORROW” as in step 608, and when the time reaches the actual day the dose is due, the countdown timer 27 switches to “TODAY” as depicted in step 610 of Fig. 10.
- the motion sensor 20 is activated when the countdown timer 27 reaches “TOMORROW” in step 608 or the day before the dose is due and remains activated when the countdown timer 27 reaches “TODAY” in step 610.
- the touch screen 16 of the reminder device 12 will turn on, e.g., be visible and/or activated, for 30 seconds and will not turn on again for another 10 minutes.
- time frames may vary and be alternatively set to different values and still fall within the scope of the present disclosure.
- the visible indicator 28 of the countdown timer 27 may be automatically activated at a set time before the date for the dose and upon sensing motion via the motion sensor 20.
- the motion sensor 20 senses the motion of any user, such as the patient or a caregiver, with the range of the reminder device 12.
- a camera such as a camera sensor, and facial recognition algorithms may alternatively be used with the reminder device 12 and/or the reminder system 10 to replace the motion sensor 20.
- the camera sensor may be trained to recognize only the patient taking the drug product.
- the visual indicator 28 of the countdown timer 27 would only activated after only motion of the actual patient is sensed, for example, limiting alarm and other proximity-based activity to the actual patient. This may be achieved using known artificial intelligence techniques, for example..
- the audible alarm of the audible indicator 22 of the reminder device 12 is activated according the audible alarm settings inputted by the user, as described above.
- the audible alarm continues for 15 seconds and the touch screen 16 simultaneously turns on, e.g., is visible, for 30 seconds.
- the touch screen 16 displays a schedule prompt to the user providing an opportunity to maintain the same dosing and reminder schedules initially input by the user or change the dosing and reminder schedules in step 612. If the user actuates the “back” button on the touch screen 16, the touch screen 16 displays the same options as provided in Fig. 7 and described above.
- the touch screen 16 also displays a reminder prompt, which provides three options for the user as depicted in step 614. Specifically, the reminder prompt on the touch screen 16 provides an option for activating the temperature timer 33 for a period of time, such as 30 minutes, after the audible alarm is activated, enabling the drug product to be prepared for the dose.
- preparing the drug product for injection includes removing the drug product 37 from the refrigerated compartment 35 and allowing the drug product 37 to be warmed to room temperature within the 30 minute time frame of the temperature timer 33. Further, once the prompt for the temperature timer 33 is selected, the touch screen 16 displays the timer in a countdown form, e.g., starting at 30 minutes, and provides an option for the user to dismiss the temperature timer at any time, e.g., such as if the drug product is prepared and ready for the dose, or indicate that the dose has been taken, which will stop the temperature timer 33 as well. If neither are selected, the temperature timer 33 will display the countdown timer 27 until the time expires and then sound an alarm, indicating the time of the temperature timer 33 has expired.
- the reminder prompt also lists the option of selecting “quiet” as a snooze feature of the reminder device 12 upon activation of the audible alarm 22.
- the audible alarm is silenced for a period of time and the reactivated to alert the user again that it is time for the dose of the drug product.
- the reminder prompt on the touch screen 16 lists the option of selecting “dose taken.” If the user selects “dose taken,” the motion sensor 20 is deactivated and the countdown timer 27 is reset on the display of the touch screen 16 according to the dosing schedule and the reminder schedule set by the user.
- the touch screen 16 of the reminder device 12 also depicts a “take now” prompt as in step 616.
- the “take now” prompt of the touch screen 16 again provides the option for activating the temperature timer 33, as described above relative to step 614.
- the “take now” prompt lists the option of selecting “dose taken,” as also described above relative to step 614.
- a method of managing reminders for a drug product may include, upon actuating the reminder device 12, displaying the countdown timer 17 on the touch screen 16 of the reminder device 12, the countdown timer 27 for reminding the user of at least one date for a dose of a drug product set by the user.
- the method may also include updating the countdown timer 27 as the at least one date of the dose approaches.
- the method may further include activating the visible indicator 28 of the countdown timer 27: (1) upon actuating the button 18 of the reminder device 12; or (2) automatically at a set time before the at least one date for the dose and upon sensing motion via the motion sensor 20.
- the method includes activating the audible alarm of the audible indicator 22 of the reminder device 22 at a time set by the user.
- the method may also include storing, via the memory 26 of the reminder device 12, one or more of the dosing schedule and the reminder schedule based on input from the user, and the dosing schedule includes the at least one date for a dose of the drug product, and the reminder schedule includes the time for activating the audible alarm.
- the method may further include automatically changing the touch screen 16 of the reminder device 12 to a color indicating the dose is past due, providing another reminder to the user.
- the method may include transmitting, again via the processor 24 of the reminder device 12, a text message reminder to the user device 44 via the wireless network 36 at the at least one date for the dose or when the dose is past due. Still further, the method may include actuating the touch screen 16 on the reminder device 12 in response to the audible alarm 22 to initiate a snooze function for the audible alarm 22 and for a period of time, and automatically reactivating the audible alarm 22 after the period of time expires. Lastly, the method may further include activating the temperature timer 33 before the date and the time for the dose, enabling the drug product to be prepared for the dose. More specifically, and in one example, the temperature timer 33 is configured to alert the user when the drug product has been out of the refrigerated compartment 35 for a sufficient time, allowing the drug product to reach a desired temperature, such as room temperature.
- the reminder device 12 and reminder system 10 help patients take their drug products on time.
- “on-time” dosing of a needed drug product improved 12% at three months and 18% at six months, and there was a simultaneous reduction in late and skipped doses using the reminder device 12.
- at least one study also found that 40% of patients took their drug product within the first hour after the audible alarm of the reminder device 12.
- adherence improvement participants in the study reported between 58-69% medication adherence for their most recent four doses, such as injections, using the reminder device 12.
- a feedback system 700 for use with the dose of the drug product is depicted, and the feedback system 700 may include a reminder device 712, as depicted in Fig. 12.
- the reminder device 712 is very similar to the reminder device 12 of the reminder system 10 described above and depicted in Figs. 1 and 2, with some additions.
- the reminder device 712 of the feedback system 700 includes a microphone and a feedback mechanism, such as a speaker, to provide feedback to a user during the dose of the drug product (in addition to the reminder features), for example and as explained more below.
- a feedback mechanism such as a speaker
- parts of the reminder device 712 of the feedback system 700 that are the same as parts of the reminder device 12 and the reminder system 10 of Figs. 1 and 2 are numbered 700 more and are not explained again in detail for the sake of brevity.
- the feedback system 700 further includes a drug delivery device to which the reminder device may be operatively coupled. So configured, feedback from one or more of the reminder device and/or a user device may be provided to the user about the dose of the drug product based on signals generated by the drug delivery device, for example, as also explained more below.
- the feedback system 700 for use during a dose of a drug product includes a wireless network 701, a drug delivery device 702 including a body 703 and an audible indicator 704Afor generating one or more audible signals.
- the audible indicator 704A may be a button or other retractable mechanism or any other part that creates a sound or “click” upon actuation of the drug delivery device 702, as is commonly understood by those having skill in the art. It will be further understood that the audible indicator 704A of the drug delivery device 702 may take the form of any other structure or part capable of generating one or more audible signals at the start of use, during use, or at the end of the use of the drug delivery device 702 and still fall within the scope of the present disclosure.
- the drug delivery device 702 may also include a visual indicator 704B for generating at least one visual signal.
- the visual indicator 704B may likewise take the form of any known structure or part of drug delivery devices capable of generating at least one visual signal, such as an light source or an LED light that turns “on” and/or emits light upon actuation of the drug delivery device 702, for example, and/or a change in state of the drug delivery device 702.
- the light source and/or LED light may change color and/or turn “off” during use and/or at the end of the use of the drug delivery device 702.
- the feedback system 700 further includes an intermediary device 705 operatively coupled to the drug delivery device 702 and the wireless network 701.
- the intermediary device 705 includes a body 706 having a microphone 707 configured to amplify the one or more audible signals generated by the drug delivery device 702.
- the intermediary device 705 also includes at least one feedback mechanism 708 carried by the body 706, a memory 709 carried by the body 706, and a processor 710 also carried by the body 706.
- the processor 710 is configured to execute logic stored on the memory 709 to cause the feedback mechanism 708 to provide feedback to the user about the dose of the drug product based on the one or more audible signals generated by the drug delivery device 702.
- the processor 710 is further configured to execute logic stored on the memory 709 to cause the feedback mechanism 708 to provide feedback to the user about the dose based on the at least one visual signal generated by the visual indicator 704B of the drug delivery device 702.
- the feedback may include one or both of an audio indication, such as a vocal indication, or a visual indication, as explained more below.
- the intermediary device 705 may further include a camera 713 that is also carried by the body 706. In this example, the processor 710 is further configured to cause the camera 713 to take a picture of the drug delivery device under certain conditions.
- the one or more audible signals generated by the drug delivery device 702 include a start of dose “click” or sound when a button or other part of the drug delivery device 702 is actuated to initiate the dose of the drug product.
- the audible signal may also include an end of the dose (EOD) “click” or sound made by the button or another part of the drug delivery device 702 when the dose of the drug product is completed.
- intermediary device 705 is able to assess the character of the EOD “click” or sound to determine if the user lifts the drug delivery device 702 early from an injection site, for example. For instance, the EOD “click” or sound may be less muffled when not in contact with the user’s skin at the injection site.
- the audible signal generated by the drug delivery device 702 may also include a continuous clicking sound made during the dose of the drug product, for example.
- the intermediary device 705 is configured to discern and process a difference in sound between the start of the dose “click”, the EOD “click” and the continuous clicking.
- the intermediary device 705 may include the reminder device 712 (Fig. 12), a smart appliance, such as a smart refrigerator 735 to which the reminder device 712 may be attached (Fig. 12).
- the intermediary device 705 may also include any other smart user device, such as a smart phone (Fig. 12), a personal computer, a tablet, a smart speaker device, such as an Alexa smart speaker or similar product, and still fall within the scope of the present disclosure.
- the at least one feedback mechanism 708 of the intermediary device 705 may include a speaker and/or a display screen, as also explained more below.
- the feedback system 700 also includes a remote computing system 711 having first and second databases (Fig. 12) and communicatively coupled to the intermediary device 705 via the wireless network 701.
- the processor 710 of the intermediary device 705 is further configured to collect data during the dose of the drug product and transmit the data to at least one of the databases of the remote computing system 711 , as explained more below.
- data collected by the intermediary device 705 during the dose of the drug product of the drug delivery device 702 may be further analyzed to understand existing features, conditions, and/or user experiences of or related to the feedback system 700 and areas for improvement of the same, for example.
- the feedback system 700 is again depicted with exemplary intermediary devices 705 included.
- the intermediary devices 705 include a reminder device 714, a smart appliance 735, and a user device 744, such as a smart phone.
- Each of these intermediary devices 705 at least includes the features described above relative to the intermediary device 705 of Fig. 11 , for example, and other features as described herein.
- the reminder device 712 includes a body 714 with the microphone 707, a feedback mechanism 708, such as a speaker 715, a display screen 716, which may include a touch screen, and a button 718.
- the display screen 716 may also be used as another type of feedback mechanism 708 of the reminder device 712, as explained more below.
- the reminder device 712 also includes a motion sensor 720 carried by the body 714. While the motion sensor 720 is disposed on a lower area of the body 714, the motion sensor 720 may alternatively be disposed on any part of the reminder device 712.
- the reminder device 12 further includes an audible indicator 722 carried by the body 714 and for generating an audible alarm, a processor 724, and a memory 726, and each of the processor 724 and memory are also carried by the body 714.
- the memory 726 stores a dosing schedule and a reminder schedule, and each of the dosing schedule and the reminder schedule are based on user input provided via the touch screen 716 of the reminder device 712, as also described more above relative to the reminder device 12.
- the dosing schedule includes at least one date for the dose inputted by the user
- the reminder schedule includes at least one time for activating the audible alarm of the audible indicator 722.
- the processor 724 is configured to access the dosing schedule and the reminder schedule and execute logic stored on the memory 26 to cause: (A) the touch screen 716 to display a countdown timer 727 for reminding the user of the at least one date for the dose.
- the countdown timer 727 updates as the at least one date for the dose approaches and comprises a visible indicator 728.
- the visible indicator 728 may include text or a color on a display of the touch screen 716, as explained more below.
- the visible indicator 728 may be activated upon actuation of the button 718 on the body 714 of the reminder device 712. Further, the visible indicator 728 may also be automatically activated at a set time before the at least one date of the dose and upon sensing motion via the motion sensor 720. Still further, the processor 724 may also execute logic stored on the memory 726 to cause the audible alarm of the audible indicator 722 to activate the at least one time for the dose, as also explained more below. As will be understood, the audible indicator 722 and the visible indicator 728 may be further feedback mechanisms of the reminder device 712.
- the reminder device 712 includes a power source 730, which may include a battery or a wired connection, a power/charge port 732, a temperature timer 733, and a magnet or magnetic portion 734.
- the power/charging port 732 is used for powering the power source 730, such as a battery, of the reminder device 712, and no data can be accessed from the reminder device 712 via this port 732.
- the magnet or magnetic portion 734 of the reminder device 712 may be attached to a surface of a refrigerated compartment 735, such as a smart refrigerator appliance, storing the drug product 737 (Fig. 12), such as the drug product for injection and of the drug delivery device 702.
- the temperature timer 733 may be activated for a period of time, such as 30 minutes, when the audible alarm 22 is activated, enabling the drug product 737 to be prepared for the dose, as also explained more below.
- the temperature timer 733 is configured to alert the user when the drug product has been out of the refrigerated compartment 735 for a sufficient time, allowing the drug product to reach a desired temperature, such as room temperature.
- the feedback system 700 also includes the wireless network 701, and the reminder device 712 may be operatively coupled to the wireless network 701 via a Wi-Fi router of the user.
- the reminder system 700 also includes at least one remote database operatively coupled to the wireless network 701.
- the reminder device 712 supports an optional Wi-Fi connection that allows it to connect to an SMS server and the at least one remote database.
- the feedback system 700 includes the remote computing system 711 that includes a first remote database 740, such as a cloud mine database, for receiving data, such as a log of information about depersonalized user actions, collected by the processor 724 and stored in the memory 726 of the reminder device 712, in one example.
- the remote computing system 711 may also include a second remote database 742 for receiving data, such as a log of information about personalized user actions, again collected by the processor 724 and stored in the memory 726 of the reminder device 712 in this example.
- the first remote database 740 includes a processor 745, a memory 746, and a network interface 747
- the second remote database 742 also includes a processor 748, a memory 749, and a network interface 750. So configured, the processors 745, 748 of each of the first and second remote databases 740, 742 receive data, such as the logs of information, from one or more of the reminder device 712 or the user device 744 (also in Fig. 12), for example, and may generate reports based on the collected information.
- the user device 744 also includes at least a processor 751, a memory 752, and a network interface 753 operatively coupled to the wireless network 701.
- the user device 744 also further includes the microphone 707 and the at least one feedback mechanism 708, such as the speaker 715 or the display screen 716, as depicted in Fig. 12.
- the feedback system 700 may provide many types of feedback to the user using various types of feedback mechanisms of various intermediary devices based on one or more signals generated by the drug delivery device 702 during the dose of the drug product.
- the at least one feedback mechanism 708 is the speaker 715 of any one of the intermediary device 705, the reminder device 712, and the user device 744.
- the processor 710, 724, 751 of the intermediary device 705, the reminder device 712, and the user device 744, respectively, is configured to cause the speaker 708 to provide feedback, such as an audio indication, including one or more of: (1) a rebroadcast of the audible signal generated by the drug delivery device 702 at a sound level higher than the sound level of the audible signal initially generated by the drug delivery device 702; (2) a vocal instruction indicating one or more of the status of the dose of the drug product or an estimate of a remaining time for the dose of the drug product, (3) an indication that the drug delivery device 702 is lifted from the injection site 750 (Fig.
- the rebroadcast and/or sound may be tailored to the environment of the user, for example. For instance, if the intermediary device 705 detects a background sound power or level that is at about 50dB, the intermediary device 705 may choose to provide the feedback to the user, e.g., provide the rebroadcast of the audible signal, at level of about 53dB so as to only be as loud as necessary without startling the user of the drug delivery device 702 during the dose of the drug product.
- the intermediary device 502 may provide feedback to the user via the audio indication that is at a level of sound greater than the background level of sound, such as about 53dB in this example.
- the intermediary device 705 may provide the vocal instruction in a language of the user’s choosing, regardless of a region.
- the at least one feedback mechanism 708 is the display screen 708, 716 of the intermediary device 705, the reminder device 712, and the user device 744.
- the processor 710, 724, 751 of each of the intermediary device 705, the reminder device 712, and the user device 744 is configured to cause the display screen 708, 716 to provide feedback including a visual indication on the display screen 708, 716.
- the visual indication includes one or more of a countdown bar 760 for providing the status of dose, as depicted in Fig. 14, and a celebration indication 762 when the dose of the drug product is completed, as depicted in Fig. 15.
- the visual indication may additionally or alternatively include one or more of a distracting reward indication 764 to minimize user perception of pain, as depicted in Fig. 16, and a report 766 providing a total time for the dose of the drug product to be completed, as depicted in Fig. 17.
- the at least one feedback mechanism 708, 722 is the audible indicator, such as the speaker 715, and the feedback provided based on the one or more audible signals generated from the drug delivery device 702 includes an audio indication, such as a vocal indication.
- the vocal indication may include one or more of: (1) a total time for the dose of the drug; (2) a celebration of completion of the dose of the drug product; (3) a countdown of time remaining in the dose of the drug product; (4) an indication that the drug delivery device 702 may be tampered with or counterfeit; and/or (5) a confirmation that the drug delivery device is locked out after completion of the dose of the drug product.
- the intermediary device 705 is able to identify such tampered or counterfeit drug delivery devices 702 based on comparing the one or more audible signals from the drug delivery device 702 to a designed audible signal of the actual, correct drug delivery device 702. If the sound of the actual audible signal received from the drug delivery device 702 matches the sound of the designed audible signal of the drug delivery device 702, no potential tampered with or counterfeit drug delivery device indications is provided by the intermediary device 705.
- the intermediary device 705 provides the feedback to the user in the form of the vocal indication in this example.
- the processor 710, 724, 751 of each of the intermediary device 705, the reminder device 712, and the user device 744 of the feedback system 700 is further configured to execute logic stored on the memory 709, 726, 752 to cause the processor 710, 724, 751 to collect data during the dose of the drug product and while receiving the one or more audible signals from the drug delivery device 702.
- the data collected may include one or more of: (1) data regarding statistics on training efficacy of administering the dose of the drug product; (2) data regarding total time for completion of the dose of the drug product; (3) data regarding an environment in which the dose of the drug product is administered; and (4) data regarding disposal of the drug delivery device 702.
- processor 710, 724, 751 is further configured to execute logic stored on the memory 709, 726, 752 to cause the processor 710, 724, 751 to transmit collected data to the at least one remote database 740, 742 of the remote computing system 711.
- the data collected and transmitted may be used for a variety of purposes.
- the data collected regarding the total time for completion of the dose of the drug product may be used to improve an understanding of product consistency.
- data collected on the environment of the dose, such as the injection may include sound, light and location of the environment of the user. This data may then be used to improve the user environment design and allow for a more robust human factors definition of user needs for future drug products, accessories, and lifecycle management efforts.
- data regarding disposal of the drug delivery device 702 may be used to better optimize container distribution and collection, such as when the user may need a replacement and a collection of a full container, for example.
- the at least one feedback mechanism 708 is the display screen 716, and the feedback provided by the feedback mechanism 708 includes one or more of: (1) an indication 770 a user complied with a prescribed dosing interval; (2) an indication 772 confirming a correct drug product was administered, e.g., such as based on sound and time intervals of the one or more audible signals; (3) a solicitation 774 regarding dose experience after the dose is completed; (4) an indication 776 of a reorder of a replacement dose of the drug product upon sensing the drug delivery device 702 stalled or a user lifted the drug delivery device 702 from an injection site prematurely; (5) an estimate of sustainability impact 778 based on a user’s geolocation at a time of the dose compared to an alternative injection site; (6) an indication 780 providing a date for a next dose of the drug product; and (7) a solicitation 782 regarding what injection site was chosen after an end of dose dick to
- the at least one feedback mechanism may additionally and/or alternatively include an audible indicator, such as the speaker 715, and each of the indications and solicitations displayed in Fig. 18 and described above may additionally and/or alternatively be provided via the audio indication, such as the vocal instruction or indication.
- the estimate may be based on comparing the distance of the user’s residence location in which dose of the drug product is administered to a point of care location the user would need to travel to receive the dose of the drug product if unable to administer at the user’s residence location. More specifically, if the user lives 50 miles from the point of care location, administering the dose of the drug product via the drug delivery device 702 at the user’s residence location saves the user from needing to take that trip to the point of care location. As a result, the user avoids associated emissions from the trip and travel.
- the data received from the solicitation may be used to provide guidance to the user at the time of the next dose of the drug product, e.g., the injection, regarding what injection site will be appropriate.
- the data received from the solicitation may be used to provide guidance to the user at the time of the next dose of the drug product, e.g., the injection, regarding what injection site will be appropriate.
- users should typically select a different time for each dose of the drug product, such as for each injection.
- the user may make a note about how the injection at a particular injection site for a particular dose of the drug product went, such as was the dose of the drug product at that site abnormally painful, hard to pinch enough skin, and/or awkward to hold the drug delivery device 702.
- This data then allows the intermediary device 705 to provide potentially further feedback including correction suggestions to a better injection site for the user and/or what accessories the user should use when administering the dose of the drug product.
- a method of providing feedback to the user during a dose of a drug product may include receiving one or more audible signals generated by the drug delivery device 702 via the intermediary device 705 and providing feedback to the user about a dose of a drug product of the drug delivery device 702 via the feedback mechanism 708 of the intermediary device 705 based on the one or more audible signals, the feedback including one or more of an audio indication, such as the vocal indication, or a visual indication.
- the method may also include collecting data, via the processor 710 of the intermediary device 705, while receiving the one or more audible signals from the drug delivery device 702, the data including one or more of: (1) data regarding statistics on training efficacy of administering the dose of the drug product; (2) data regarding total time for completion of the dose of the drug product; (3) data regarding an environment in which the dose of the drug product is administered; and (4) data regarding disposal of the drug delivery device 702.
- the method may also include transmitting the data, via the processor 710 of the intermediary device 705, to the at least one remote database 740, 742 via the wireless network 701.
- receiving one or more audible signals generated by the drug delivery device 702 via the intermediary device 705 may include receiving one or more audible signals generated by the drug delivery device 702 via the microphone 707 of the intermediary device 705.
- providing feedback to the user about the dose of the drug product of the drug delivery device 702 via the feedback mechanism 708 of the intermediary device 705 based on the one or more audible signals may include providing feedback to the user about the dose of the drug product of the drug delivery device 702 via the speaker 715.
- the feedback may include the audio indication
- the audio indication may include a vocal instruction including one or more of: (1) a rebroadcast of the audible signal generated by the drug delivery device 702 a sound level higher than the sound level of the audible signal initially generated by the drug delivery device 702 via the speaker 715; (2) a vocal instruction indicating one or more of the status of the dose of the drug product or an estimate of the remaining time for the dose of the drug product in the drug delivery device 702; (3) an indication that the drug delivery device 702 is lifted from an injection site based on an acoustic character of the audible signal generated from the drug delivery device 702; and (4) a vocal instruction that the dose of the drug product by the drug delivery device 702 is complete based on a number of audible signals generated by the drug delivery device 702.
- providing feedback to the user about the dose of the drug product of the drug delivery device 702 via the feedback mechanism 708 of the intermediary device 705 based on the one or more audible signals may include providing feedback to the user about a dose of a drug product of the drug delivery device 702 via a display screen 716, and the feedback includes a visual indication on the display screen 716.
- the visual indication includes one or more of a countdown bar for providing the status of the dose, a celebration indication when the dose of the drug product is completed, a distracting reward indication to minimize user perception of pain, and a report providing a total time for the dose of the drug product to be completed.
- the intermediary device 705 of the feedback system 700 and method is able to transform existing audible spectra from existing feedback mechanisms on known drug delivery devices into electromagnetic spectra via the wireless connection of the intermediary device without having to add a wireless module to the drug delivery device.
- helpful feedback via the intermediary device 705, such as the reminder device 712 or the smart user device 744 is provided to the user during the dose of the drug product in a cost effective and sustainable manner.
- the usability of the drug delivery devices is enhanced at several stages, providing both feedback and training to the user.
- initial training using the drug delivery device 702 and ongoing use of the drug delivery device 702 is enhanced with the ongoing feedback of the feedback system 700 and methods of the present disclosure.
- the feedback system 700 and method are able to assist with continuous improvement of the use of the drug delivery device 702 while remaining cost effective and environmentally sustainable.
- voluntary data collection may also provide the ability for payers to receive assurances that preventative therapies are being administered in a manner that lowers payer fiscal risk and allows for improved value proposition for therapy and drug delivery entities.
- the above description describes various devices, systems, and methods related to reminders and feedback for doses of a drug product.
- the device, components, subsystems, or methods can be used with a drug product, for example certain methods according to the present disclosure may include injection of a drug product after one or more reminders, where the drug products can include but are not limited to the drug products identified below as well as their generic and biosimilar counterparts.
- the term drug product, as used herein, can be used interchangeably with other similar terms and can be used to refer to any type of medicament or therapeutic material including traditional and non-traditional pharmaceuticals, nutraceuticals, supplements, biologies, biologically active agents and compositions, large molecules, biosimilars, bioequivalents, therapeutic antibodies, polypeptides, proteins, small molecules and generics.
- Non-therapeutic injectable materials are also encompassed.
- the drug product may be in liquid form, a lyophilized form, or in a reconstituted from lyophilized form.
- the following example list of drug products should not be considered as all-inclusive or limiting.
- the drug product will be contained in a reservoir of a drug delivery device.
- the reservoir is a primary container that is either filled or pre-filled for treatment with the drug.
- the primary container can be a vial, a cartridge or a pre-filled syringe.
- the reservoir of the drug delivery device may be filled with or the device can be used with colony stimulating factors, such as granulocyte colony-stimulating factor (G-CSF).
- G-CSF agents include but are not limited to Neulasta® (pegfilgrastim, pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G-CSF) and Neupogen® (filgrastim, G- CSF, hu-MetG-CSF), UDENYCA® (pegfilgrastim-cbqv), Ziextenzo® (LA-EP2006; pegfilgrastim-bmez), or FULPHILA (pegfilgrastim-bmez).
- Neulasta® pegfilgrastim, pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G-CSF
- Neupogen® filgrastim, G- CSF, hu
- the drug delivery device may contain or be used with an erythropoiesis stimulating agent (ESA), which may be in liquid or lyophilized form.
- ESA erythropoiesis stimulating agent
- An ESA is any molecule that stimulates erythropoiesis.
- an ESA is an erythropoiesis stimulating protein.
- erythropoiesis stimulating protein means any protein that directly or indirectly causes activation of the erythropoietin receptor, for example, by binding to and causing dimerization of the receptor.
- Erythropoiesis stimulating proteins include erythropoietin and variants, analogs, or derivatives thereof that bind to and activate erythropoietin receptor; antibodies that bind to erythropoietin receptor and activate the receptor; or peptides that bind to and activate erythropoietin receptor.
- Erythropoiesis stimulating proteins include, but are not limited to, Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa), Dynepo® (epoetin delta), Mircera® (methyoxy polyethylene glycol-epoetin beta), Hematide®, MRK- 2578, INS-22, Retacrit® (epoetin zeta), Neorecormon® (epoetin beta), Silapo® (epoetin zeta), Binocrit® (epoetin alfa), epoetin alfa Hexal, Abseamed® (epoetin alfa), Ratioepo® (epoetin theta), Eporatio® (epoetin theta), Biopoin® (epoetin theta), epoetin alfa,
- proteins are the specific proteins set forth below, including fusions, fragments, analogs, variants or derivatives thereof: OPGL specific antibodies, peptibodies, related proteins, and the like (also referred to as RANKL specific antibodies, peptibodies and the like), including fully humanized and human OPGL specific antibodies, particularly fully humanized monoclonal antibodies; Myostatin binding proteins, peptibodies, related proteins, and the like, including myostatin specific peptibodies; IL-4 receptor specific antibodies, peptibodies, related proteins, and the like, particularly those that inhibit activities mediated by binding of IL-4 and/or IL-13 to the receptor; Interleukin 1-receptor 1 (“IL1-R1”) specific antibodies, peptibodies, related proteins, and the like; Ang2 specific antibodies, peptibodies, related proteins, and the like; NGF specific antibodies, peptibodies, related proteins, and the like; CD22
- IL1-R1 Interleuk
- Patent No. 7,153,507 Tysabri® (natalizumab, anti-a4integrin mAb); Valortim® (MDX-1303, anti-B. anthracis protective antigen mAb); ABthraxTM; Xolair® (omalizumab); ETI211 (anti-MRSA mAb); IL-1 trap (the Fc portion of human lgG1 and the extracellular domains of both IL-1 receptor components (the Type I receptor and receptor accessory protein)); VEGF trap (Ig domains of VEGFR1 fused to lgG1 Fc); Zenapax® (daclizumab); Zenapax® (daclizumab, anti-IL-2Ra mAb); Zevalin® (ibritumomab tiuxetan); Zetia® (ezetimibe); Orencia® (atacicept, TACI-lg); anti-CD80 monoclonal antibody (galiximab); anti-CD23
- the drug delivery device may contain or be used with a sclerostin antibody, such as but not limited to romosozumab, blosozumab, BPS 804 (Novartis), EvenityTM (romosozumab-aqqg), another product containing romosozumab for treatment of postmenopausal osteoporosis and/or fracture healing and in other embodiments, a monoclonal antibody (IgG) that binds human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
- a sclerostin antibody such as but not limited to romosozumab, blosozumab, BPS 804 (Novartis), EvenityTM (romosozumab-aqqg), another product containing romosozumab for treatment of postmenopausal osteoporosis and/or fracture healing and in other embodiments, a monoclonal antibody (I
- PCSK9 specific antibodies include, but are not limited to, Repatha® (evolocumab) and Praluent® (alirocumab).
- the drug delivery device may contain or be used with rilotumumab, bixalomer, trebananib, ganitumab, conatumumab, motesanib diphosphate, brodalumab, vidupiprant or panitumumab.
- the reservoir of the drug delivery device may be filled with or the device can be used with IMLYGIC® (talimogene laherparepvec) or another oncolytic HSV for the treatment of melanoma or other cancers including but are not limited to OncoVEXGALV/CD; OrienXOIO; G207, 1716; NV1020; NV12023; NV1034; and NV1042.
- the drug delivery device may contain or be used with endogenous tissue inhibitors of metalloproteinases (TIMPs) such as but not limited to TIMP-3.
- TIMP-3 tissue inhibitors of metalloproteinases
- the drug delivery device may contain or be used with Aimovig® (erenumab-aooe), anti-human CGRP-R (calcitonin gene-related peptide type 1 receptor) or another product containing erenumab for the treatment of migraine headaches.
- Antagonistic antibodies for human calcitonin gene-related peptide (CGRP) receptor such as but not limited to erenumab and bispecific antibody molecules that target the CGRP receptor and other headache targets may also be delivered with a drug delivery device of the present disclosure.
- bispecific T cell engager (BiTE®) antibodies such as but not limited to BLINCYTO® (blinatumomab) can be used in or with the drug delivery device of the present disclosure.
- the drug delivery device may contain or be used with an APJ large molecule agonist such as but not limited to apelin or analogues thereof.
- a therapeutically effective amount of an anti-thymic stromal lymphopoietin (TSLP) or TSLP receptor antibody is used in or with the drug delivery device of the present disclosure.
- the drug delivery device may contain or be used with AvsolaTM (infliximab-axxq), anti- TNF a monoclonal antibody, biosimilar to Remicade® (infliximab) (Janssen Biotech, Inc.) or another product containing infliximab for the treatment of autoimmune diseases.
- the drug delivery device may contain or be used with Kyprolis® (carfilzomib), (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2- ((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide, or another product containing carfilzomib for the treatment of multiple myeloma.
- Kyprolis® carfilzomib
- the drug delivery device may contain or be used with Otezla® (apremilast), N-[2-[(1 S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1 ,3-dioxo- 1H-isoindol-4-yl]acetamide, or another product containing apremilast for the treatment of various inflammatory diseases.
- Otezla® aspremilast
- the drug delivery device may contain or be used with ParsabivTM (etelcalcetide HCI, KAI-4169) or another product containing etelcalcetide HCI for the treatment of secondary hyperparathyroidism (sHPT) such as in patients with chronic kidney disease (KD) on hemodialysis.
- the drug delivery device may contain or be used with ABP 798 (rituximab), a biosimilar candidate to Rituxan®/MabTheraTM, or another product containing an anti-CD20 monoclonal antibody.
- the drug delivery device may contain or be used with a VEGF antagonist such as a non-antibody VEGF antagonist and/or a VEGF-Trap such as aflibercept (Ig domain 2 from VEGFR1 and Ig domain 3 from VEGFR2, fused to Fc domain of lgG1).
- a VEGF antagonist such as a non-antibody VEGF antagonist and/or a VEGF-Trap such as aflibercept (Ig domain 2 from VEGFR1 and Ig domain 3 from VEGFR2, fused to Fc domain of lgG1).
- the drug delivery device may contain or be used with ABP 959 (eculizumab), a biosimilar candidate to Soliris®, or another product containing a monoclonal antibody that specifically binds to the complement protein C5.
- the drug delivery device may contain or be used with Rozibafusp alfa (formerly AMG 570) is a novel bispecific antibody-peptide conjugate that simultaneously blocks ICOSL and BAFF activity.
- the drug delivery device may contain or be used with Omecamtiv mecarbil, a small molecule selective cardiac myosin activator, or myotrope, which directly targets the contractile mechanisms of the heart, or another product containing a small molecule selective cardiac myosin activator.
- the drug delivery device may contain or be used with Sotorasib (formerly known as AMG 510), a KRAS G12C small molecule inhibitor, or another product containing a KRAS G12C small molecule inhibitor.
- the drug delivery device may contain or be used with Tezepelumab, a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP), or another product containing a human monoclonal antibody that inhibits the action of TSLP.
- the drug delivery device may contain or be used with AMG 714, a human monoclonal antibody that binds to Interleukin-15 (IL-15) or another product containing a human monoclonal antibody that binds to Interleukin-15 (IL- 15).
- the drug delivery device may contain or be used with AMG 890, a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a), or another product containing a small interfering RNA (siRNA) that lowers lipoprotein(a).
- the drug delivery device may contain or be used with ABP 654 (human lgG1 kappa antibody), a biosimilar candidate to Stelara®, or another product that contains human lgG1 kappa antibody and/or binds to the p40 subunit of human cytokines interleukin (IL)-12 and IL-23.
- the drug delivery device may contain or be used with AmjevitaTM or AmgevitaTM (formerly ABP 501) (mab anti-TNF human lgG1), a biosimilar candidate to Humira®, or another product that contains human mab anti-TNF human lgG1.
- the drug delivery device may contain or be used with AMG 160, or another product that contains a half-life extended (HLE) anti-prostate-specific membrane antigen (PSMA) x anti-CD3 BiTE® (bispecific T cell engager) construct.
- HLE half-life extended
- PSMA anti-prostate-specific membrane antigen
- the drug delivery device may contain or be used with AMG 119, or another product containing a delta-like ligand 3 (DLL3) CAR T (chimeric antigen receptor T cell) cellular therapy. In some embodiments, the drug delivery device may contain or be used with AMG 119, or another product containing a delta-like ligand 3 (DLL3) CAR T (chimeric antigen receptor T cell) cellular therapy. In some embodiments, the drug delivery device may contain or be used with AMG 133, or another product containing a gastric inhibitory polypeptide receptor (GIPR) antagonist and GLP-1R agonist.
- GIPR gastric inhibitory polypeptide receptor
- the drug delivery device may contain or be used with AMG 171 or another product containing a Growth Differential Factor 15 (GDF15) analog.
- the drug delivery device may contain or be used with AMG 176 or another product containing a small molecule inhibitor of myeloid cell leukemia 1 (MCL- 1).
- the drug delivery device may contain or be used with AMG 199 or another product containing a half- life extended (HLE) bispecific T cell engager construct (BiTE®).
- the drug delivery device may contain or be used with AMG 256 or another product containing an anti-PD-1 x IL21 mutein and/or an IL-21 receptor agonist designed to selectively turn on the Interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells.
- the drug delivery device may contain or be used with AMG 330 or another product containing an anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) construct.
- the drug delivery device may contain or be used with AMG 404 or another product containing a human anti-programmed cell death-1 (PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors.
- the drug delivery device may contain or be used with AMG 427 or another product containing a half-life extended (HLE) anti-fms-like tyrosine kinase 3 (FLT3) x anti-CD3 BiTE® (bispecific T cell engager) construct.
- the drug delivery device may contain or be used with AMG 430 or another product containing an anti-Jagged-1 monoclonal antibody.
- the drug delivery device may contain or be used with AMG 506 or another product containing a multi-specific FAP x 4-1 BB-targeting DARPin® biologic under investigation as a treatment for solid tumors.
- the drug delivery device may contain or be used with AMG 509 or another product containing a bivalent T-cell engager and is designed using XmAb® 2+1 technology.
- the drug delivery device may contain or be used with AMG 562 or another product containing a half-life extended (HLE) CD19 x CD3 BiTE® (bispecific T cell engager) construct.
- the drug delivery device may contain or be used with Efavaleukin alfa (formerly AMG 592) or another product containing an IL-2 mutein Fc fusion protein.
- the drug delivery device may contain or be used with AMG 596 or another product containing a CD3 x epidermal growth factor receptor vlll (EGFRvlll) BiTE® (bispecific T cell engager) molecule.
- the drug delivery device may contain or be used with AMG 673 or another product containing a half-life extended (HLE) anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) construct.
- the drug delivery device may contain or be used with AMG 701 or another product containing a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 BiTE® (bispecific T cell engager) construct.
- the drug delivery device may contain or be used with AMG 757 or another product containing a half-life extended (HLE) anti- deltalike ligand 3 (DLL3) x anti-CD3 BiTE® (bispecific T cell engager) construct.
- the drug delivery device may contain or be used with AMG 910 or another product containing a half-life extended (HLE) epithelial cell tight junction protein claudin 18.2 x CD3 BiTE® (bispecific T cell engager) construct.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22733770.6A EP4341945A1 (en) | 2021-05-17 | 2022-05-10 | Feedback system and method for a drug product |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163189414P | 2021-05-17 | 2021-05-17 | |
US63/189,414 | 2021-05-17 | ||
US202263318385P | 2022-03-09 | 2022-03-09 | |
US63/318,385 | 2022-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022245574A1 true WO2022245574A1 (en) | 2022-11-24 |
Family
ID=82214197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/028430 WO2022245574A1 (en) | 2021-05-17 | 2022-05-10 | Feedback system and method for a drug product |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4341945A1 (en) |
WO (1) | WO2022245574A1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153507B2 (en) | 2001-08-23 | 2006-12-26 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
US20090134181A1 (en) * | 2005-07-13 | 2009-05-28 | Vitality, Inc. | Medication dispenser with automatic refill |
US20090281835A1 (en) * | 2008-05-07 | 2009-11-12 | Ravindra Patwardhan | Medical prescription scheduler for reminding and compliance |
US20130339026A1 (en) * | 2012-06-13 | 2013-12-19 | Shawn Lee | Portable electronic reminder device |
GB2520054A (en) * | 2013-11-08 | 2015-05-13 | Sarah Luisa Smith | A device to control administration of medicine |
CN104546491B (en) * | 2014-08-26 | 2017-10-27 | 董问天 | Medication alert and statistical system and medication smart electronicses system |
US20190228851A1 (en) * | 2017-02-10 | 2019-07-25 | Rajesh Rawal | Systems, methods, and apparatuses for managing adherence to a regimen |
US10751259B1 (en) * | 2017-10-09 | 2020-08-25 | Banpil Photonics, Inc. | Smart bottle system and methods thereof |
US20210046239A1 (en) * | 2017-02-24 | 2021-02-18 | Sanofi | Packaging assembly |
-
2022
- 2022-05-10 EP EP22733770.6A patent/EP4341945A1/en active Pending
- 2022-05-10 WO PCT/US2022/028430 patent/WO2022245574A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153507B2 (en) | 2001-08-23 | 2006-12-26 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
US20090134181A1 (en) * | 2005-07-13 | 2009-05-28 | Vitality, Inc. | Medication dispenser with automatic refill |
US20090281835A1 (en) * | 2008-05-07 | 2009-11-12 | Ravindra Patwardhan | Medical prescription scheduler for reminding and compliance |
US20130339026A1 (en) * | 2012-06-13 | 2013-12-19 | Shawn Lee | Portable electronic reminder device |
GB2520054A (en) * | 2013-11-08 | 2015-05-13 | Sarah Luisa Smith | A device to control administration of medicine |
CN104546491B (en) * | 2014-08-26 | 2017-10-27 | 董问天 | Medication alert and statistical system and medication smart electronicses system |
US20190228851A1 (en) * | 2017-02-10 | 2019-07-25 | Rajesh Rawal | Systems, methods, and apparatuses for managing adherence to a regimen |
US20210046239A1 (en) * | 2017-02-24 | 2021-02-18 | Sanofi | Packaging assembly |
US10751259B1 (en) * | 2017-10-09 | 2020-08-25 | Banpil Photonics, Inc. | Smart bottle system and methods thereof |
Also Published As
Publication number | Publication date |
---|---|
EP4341945A1 (en) | 2024-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230120569A1 (en) | Drug Delivery Device with Messaging Label | |
KR102416904B1 (en) | Systems and methods for remotely processing data collected by a drug delivery device | |
US11207460B2 (en) | Drug delivery storage device and system | |
US20190328965A1 (en) | Drug delivery device with placement detection | |
US20200261657A1 (en) | Auto-injector with signaling electronics | |
WO2022245574A1 (en) | Feedback system and method for a drug product | |
US20220395635A1 (en) | Drug delivery system and method of use | |
US20220072224A1 (en) | Continuous dosing systems and approaches | |
EP4048345A1 (en) | Drug delivery device and system | |
US20240066206A1 (en) | Temperature indicator for drug delivery device | |
US20230001099A1 (en) | Lockout mechanism for drug delivery device | |
US20220409817A1 (en) | Syringes, assemblies, and methods of manufacture | |
US20230381424A1 (en) | Drug delivery device assembly and accessory for drug delivery device | |
WO2022245918A1 (en) | Systems and methods to evaluate inactivation kinetics of a biological indicator | |
WO2023064119A1 (en) | Characterization apparatus for drug delivery devices or subcomponents thereof | |
CA3213303A1 (en) | Systems for out-patient treatment of a patient, and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22733770 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18561341 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022733770 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022733770 Country of ref document: EP Effective date: 20231218 |